within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04B_Urologicals.G04BD06_Propiverine;

model Propiverine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 5.833333333333333e-06,
    adminDuration = 600,
    adminMass = 15 / 1000000,
    adminCount = 1,
    Vd = 0.0157,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005333333333333333,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Propiverine</td></tr><tr><td>ATC code:</td><td>G04BD06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>15</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>15.7</td><td>L</td></tr>
    <tr><td>clearance:</td><td>350</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Propiverine is an antimuscarinic drug used for the treatment of overactive bladder and urinary incontinence. It acts by inhibiting acetylcholine on smooth muscle in the urinary bladder. The drug is approved and currently used in clinical practice for management of urinary frequency, urgency, and urge incontinence.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Weiss, M (2023). Is the One-Compartment Model with First Order Absorption a Useful Approximation?. <i>Pharmaceutical research</i> 40(9) 2147–2153. DOI:<a href=\"https://doi.org/10.1007/s11095-023-03582-1\">10.1007/s11095-023-03582-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37594592/\">https://pubmed.ncbi.nlm.nih.gov/37594592</a></p></li><li><p>Weiss, M, &amp; Siegmund, W (2023). Dependence of Bioavailability on Mean Absorption Time: What Does It Tell Us?. <i>The AAPS journal</i> 25(3) 36–None. DOI:<a href=\"https://doi.org/10.1208/s12248-023-00803-8\">10.1208/s12248-023-00803-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37016156/\">https://pubmed.ncbi.nlm.nih.gov/37016156</a></p></li><li><p>Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. <i>Clinical pharmacokinetics</i> 42(14) 1243–1285. DOI:<a href=\"https://doi.org/10.2165/00003088-200342140-00004\">10.2165/00003088-200342140-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14606931/\">https://pubmed.ncbi.nlm.nih.gov/14606931</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G04BD06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Propiverine;
